Traitement Cancer du poumon en Israël — recevez 3 correspondances personnalisées de cliniques

Israeli oncologists use advanced genetic screening and biomarker analysis to determine treatment candidacy. Next-generation sequencing (NGS) identifies driver mutations like EGFR and ALK for targeted therapy. Immunotherapy eligibility depends primarily on PD-L1 expression levels and microsatellite instability (MSI) testing within JCI-accredited facilities.

• Genetic screening: Tests identify actionable mutations including ROS1, BRAF, RET, and KRAS.
• Biomarker profiling: Specialists measure PD-L1 protein expression to predict immunotherapy response.
• Liquid biopsies: Doctors use blood-based ctDNA testing if tissue samples are insufficient.
• Precision platforms: AI-driven tools like OncoHost predict immunotherapy resistance before treatment begins.
• Fitness assessment: Oncologists evaluate organ function and ECOG status to ensure safety.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky serve over 400,000 patients annually, creating a massive data pool for precision medicine. Leading specialists like Dr Ofer Merimsky utilize this volume to refine treatment protocols. Their experience with over 900 procedures helps them identify which patients will benefit most from targeted drugs versus standard chemotherapy.

Patient Consensus: Patients in Israel note that comprehensive mutation testing often shifts treatment plans away from chemo. They find that confirming tissue quality early prevents the need for repeat biopsies during the diagnostic phase.

Israel offers advanced lung cancer care including immunotherapy, targeted therapy, and robotic surgery. Centres use molecular profiling to identify genetic mutations. This allows for precision medicines like osimertinib. High-tech radiation like CyberKnife and VMAT provides non-invasive options for complex or inoperable tumours.

• Precision medicine: Clinics use genomic profiling for mutations like EGFR, ALK, and KRAS.
• Immunotherapy: Access drugs like Keytruda or Opdivo to help the immune system.
• Robotic surgery: Surgeons use Da Vinci systems for precise, minimally invasive lobectomies.
• Radiosurgery: CyberKnife and SBRT deliver high-dose radiation while sparing healthy lung tissue.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky serve over 1,800,000 patients annually. They often provide access to novel therapies through clinical trials before they are widely available. For instance, Dr Ofer Merimsky at Sourasky has overseen over 900 procedures. This volume ensures specialists handle even the most complex Stage IV cases with high proficiency.

Patient Consensus: Patients in Israel value the fast, integrated diagnostic work-up. They note that molecular profiling often unlocks new targeted therapy options that were not available in their home countries.

Patients can obtain a remote second opinion from Israeli specialists before travelling. Major centres use telehealth frameworks for international case reviews. Senior oncologists evaluate diagnostic files and scans via video platforms. This process confirms diagnoses and outlines advanced treatment roadmaps digitally.

• Structured review: Specialists meticulously re-evaluate raw PET-CT scans and biopsy pathology results.
• Senior expertise: Opinions often come from department heads or Forbes-listed top specialists.
• Digital framework: Consultations occur via secure video conferencing platforms like Zoom or Skype.
• Formal reports: Patients receive translated medical reports with specific treatment recommendations.

Bookimed Expert Insight: Israeli oncology centres excel at molecular matching for lung cancer. Specialists like Dr Nir Peled and Dr Jair Bar focus on specific genetic mutations. An early remote review can confirm if advanced immunotherapies like Keytruda are suitable. This often prevents unnecessary travel for patients whose cases don't require surgical intervention.

Patient Consensus: Individuals note that remote reviews provide clarity on local treatment plans versus Israeli options. Many find that sending full pathology and genetic testing results ensures the most accurate remote assessment. Patients from Australia value comparing these expert Israeli insights with their local multi-disciplinary team recommendations.

Israel's leading lung cancer oncologists include Prof. Ofer Merimsky at Sourasky Medical Center, Prof. Jair Bar at Sheba Medical Center, and Prof. Nir Peled at Herzliya Medical Center. These specialists lead major thoracic units. They focus on personalised immunotherapy and advanced targeted treatments.

• Prof. Ofer Merimsky: Heads lung cancer services at Sourasky. He has handled 900+ procedures.
• Prof. Jair Bar: Chairs the Israel Lung Cancer Group. He leads Sheba's thoracic oncology.
• Prof. Nir Peled: Specialises in immuno-oncology. He completed a lung cancer fellowship in America.
• Dr. Ari Raphael: Senior oncologist at Sourasky. He focuses on molecular profiling and immunotherapy.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky serve over 400,000 patients annually. They often combine treatments into single-visit protocols. This efficiency is why medical tourists rank Israel among the top 10 global destinations. These JCI-accredited facilities offer rare specialised services like celiac plexus radiosurgery and CAR-T immunotherapy.

Patient Consensus: Patients in Israel emphasise finding specialists who join multidisciplinary tumour boards. They note it is essential to complete biomarker testing like EGFR or PD-L1 before finishing any long-term treatment plan.

Patients should plan for a total stay of 3 to 14 days in Israel for diagnostics or surgery. Complex therapies like radiotherapy or chemotherapy cycles can extend this period to 8 weeks. Specialists use JCI-accredited facilities in Tel Aviv and Haifa to manage rapid diagnostic workups.

• Diagnostic phase: Staging and multi-disciplinary board reviews typically require 3 to 7 working days.
• Surgical duration: Hospitalisation usually lasts 1 day for minimally invasive video-assisted thoracic surgery (VATS).
• Post-op monitoring: Patients must stay 6 to 10 days after discharge to ensure air-travel safety.
• Systemic therapy: Single chemotherapy or immunotherapy cycles often require a 3 to 4 week stay.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky often compress multi-step diagnostics into 72 hours. While a diagnostic package may only require 5 hotel nights, patients should note that pathology record transfers can cause delays. Bringing original pathology slides from Australia or requesting digital genomic profiling interpretation in advance can shave 4 days off the initial stay.

Patient Consensus: Patients note that staging and specialist reviews take longer than expected, making flexible return flights essential. Experience at Sourasky showed that everything was organised in a timely manner, but individuals should always confirm when they are medically cleared for the long-haul flight back to Australia.

Lung cancer care in Israel involves a multidisciplinary team led by medical oncologists, thoracic surgeons, and radiotherapists. Experts like Professor Ofer Merimsky and Professor Nir Peled specialize in personalized immunotherapy and innovative chemo-radiotherapy protocols within JCI-accredited centers to improve patient results.

• Medical oncologists. They manage drug therapies like immunotherapy and chemotherapy for non-small cell lung cancer.
• Thoracic surgeons. Specialists like Dr. Lael Anson Best perform complex operations to remove lung tumors.
• Radiation oncologists. Experts use precision techniques like stereotactic radiosurgery to target tumors with high-energy beams.
• Pulmonologists. These specialists use advanced diagnostic technologies to evaluate airway health and tumor stages.

Bookimed Expert Insight: Leading Israeli specialists often hold dual certifications or rare combinations of expertise. For example, Dr. Raphael Pfeffer is board-certified in both oncology and radiology. This allows a single expert to oversee both the tumor biology and the high-tech imaging required for precise radiation planning.

Patient Consensus: Patients often mention how comfortable they feel when doctors explain the whole process in simple terms. One patient noted that the coordination between the surgeon and the oncologist made them feel their care was a joint effort.

Lung cancer doctors in Israel specialize in personalized treatments using molecular genetic profiling and immunotherapy. Experts like Dr. Nir Peled at Herzliya Medical Center and Dr. Ari Raphael at Sourasky Medical Center tailor therapies based on genomic sequencing to target specific tumor mutations.

• Molecular profiling. Dr. Ari Raphael uses T-cell sequencing to predict individual responses to immunotherapy.
• Targeted protocols. Prof. Jair Bar at Sheba chairs the national lung cancer group focusing on resistance.
• Integrative radiotherapy. Dr. Yaacov Lawrence at Sheba leads translational research for individualized precision radiation protocols.
• Multidisciplinary surgery. Dr. Lael Anson Best at Rambam performs minimally invasive thoracic surgeries for complex cases.

Bookimed Expert Insight: Israeli specialists often hold dual qualifications in oncology and biology. Prof. Jair Bar and Prof. Raanan Berger both hold PhDs in molecular biology. This allows them to translate laboratory genomic data directly into personalized clinical protocols for advanced lung cancer cases.

Patient Consensus: Patients often feel relieved when specialists review their tumor genetics to suggest targeted drugs. They notice a clear focus on finding specific treatments that work for their unique cancer stage.

Israeli lung cancer doctors lead global research in immunotherapy and genomic medicine. Specialists like Dr. Nir Peled and Dr. Ari Raphael chair international committees and lead innovative molecular trials. These doctors integrate real-time research with clinical care to provide personalized therapies for advanced thoracic malignancies.

• Molecular research. Dr. Ari Raphael at Sourasky uses T-cell sequencing to predict immunotherapy success.
• Protocol development. Dr. Ofer Merimsky developed unique lung cancer protocols that combine chemo-radiotherapy.
• International leadership. Dr. Nir Peled chairs the IASLC committee focused on early cancer detection.
• Translational labs. Dr. Jair Bar operates a research lab investigating how tumors resist immunotherapy.

Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky operate dedicated translational research units within the hospital. This means researchers like Dr. Raanan Berger and Dr. Yaacov Lawrence can immediately apply lab findings to patient care. Patients benefit from this integration because the most senior specialists often serve as principal investigators for international phase I-III clinical trials.

Patient Consensus: Patients emphasize the importance of asking about genetic testing and immunotherapy trials before beginning standard care. They felt more confident when doctors clearly explained how newer research protocols could work alongside traditional surgery or radiation.

Thoracic surgeons in Israel perform advanced surgeries using minimally invasive VATS and Da Vinci robotic systems. Specialists like Dr. Lael Anson Best at Rambam Medical Center have completed 1,000+ complex procedures. They focus on lung-sparing techniques like segmentectomy to preserve healthy tissue and speed up recovery.

• Minimally invasive surgery. Surgeons use VATS, which uses small incisions to reduce post-operative pain and scarring.
• Robotic-assisted systems. The Da Vinci system allows for higher precision during complex lung or mediastinal resections.
• Lung-sparing techniques. Doctors perform wedge resections or segmentectomies to remove tumors while saving functional lung tissue.
• Advanced oncology protocols. Dr. Ofer Merimsky at Sourasky uses chemo-radiotherapy before surgery to shrink difficult tumors.

Bookimed Expert Insight: Israeli thoracic surgeons often integrate molecular genetics into surgical planning. Dr. Jair Bar at Sheba Medical Center heads a unit focusing on immunotherapy and genetics. This ensures that surgery is part of a personalized plan, especially for patients with advanced or treatment-resistant cancer.

Patient Consensus: Many patients prioritize asking about lung-sparing options like segmentectomy over traditional lobectomy to maintain better breathing capacity. They noticed that while recovery is faster with robotic surgery, managing post-operative fatigue and drains remains a vital step.

Specialists in Israel determine lung cancer treatment plans through multidisciplinary tumor boards where surgeons, oncologists, and radiologists collaborate. They use genomic profiling and T-cell sequencing to identify specific mutations, ensuring every patient receives a personalized therapy roadmap based on their unique biology.

• Molecular tumor boards. Teams review genomic data to select targeted therapies for specific genetic mutations.
• Customized protocols. Dr. Ofer Merimsky at Sourasky develops unique protocols combining chemo-radiotherapy before surgery.
• Immunotherapy research. Dr. Jair Bar leads studies on immunotherapy resistance to optimize drug selection.
• Translational oncology. Dr. Ari Raphael at Sourasky uses T-cell repertoire sequencing for advanced innovation.

Bookimed Expert Insight: Israeli lung cancer specialists often hold dual certifications in oncology and radiotherapy. For example, Dr. Raphael Pfeffer at Assuta and Dr. Jair Bar at Sheba are board-certified in both. This dual expertise allows one doctor to manage both radiation and drug therapy. This integration usually leads to faster transitions between treatment phases compared to separate departments.

Patient Consensus: Patients often mention how quickly doctors move from the first consultation to a full treatment plan. Many were surprised that a single specialist could coordinate both their chemotherapy and radiation sessions efficiently.